As the country registers an increase in new HIV infections, stakeholders have called for improved access to prevention tools.
The Imbokodo vaccine, made by Johnson & Johnson began in 2017 and involved 2600 women in Malawi, Mozambique, South Africa, Zambia and Zimbabwe. The results from the study showed that the vaccine has 25.2 per cent efficacy against the HIV virus, which is too low to make the vaccine useful.With the disappointing news, a public health expert, Tosin Alaka told me that it is important for Nigerian government to increase the options of preventive tools to Nigerians from which they can choose from.
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: GuardianNigeria - 🏆 1. / 94 Read more »
Source: GuardianNigeria - 🏆 1. / 94 Read more »